THK-5351 F-18

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125290

CAS#: 1707148-68-2

Description: 18F-THK-5351 is a novel radiotracer that demonstrates high binding selectivity and affinity for tau pathology and exhibits better pharmacokinetics in the living brain than previous THK tau probes.

Chemical Structure

img
THK-5351 F-18
CAS# 1707148-68-2
Instruction

Theoretical Analysis

MedKoo Cat#: 125290
Name: THK-5351 F-18
CAS#: 1707148-68-2
Chemical Formula: C18H1818FN3O2
Exact Mass: 326.14
Molecular Weight: 326.360
Elemental Analysis: C, 66.24; H, 5.56; F, 5.52; N, 12.88; O, 9.80

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: THK-5351 F-18; UNII-X7F1935FL1; (18F)(S)-THK-5351; X7F1935FL1

IUPAC/Chemical Name: (S)-1-(fluoro-18F)-3-((2-(6-(methylamino)pyridin-3-yl)quinolin-6-yl)oxy)propan-2-ol

InChi Key: DLVXFZWSPCOWSN-DHZJDKHOSA-N

InChi Code: InChI=1S/C18H18FN3O2/c1-20-18-7-3-13(10-21-18)17-5-2-12-8-15(4-6-16(12)22-17)24-11-14(23)9-19/h2-8,10,14,23H,9,11H2,1H3,(H,20,21)/t14-/m1/s1/i19-1

SMILES Code: CNC1=CC=C(C=N1)C2=NC3=C(C=C2)C=C(OC[C@H](O)C[18F])C=C3

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 326.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Oh M, Oh JS, Oh SJ, Lee SJ, Roh JH, Kim WR, Seo HE, Kang JM, Seo SW, Lee JH,
Na DL, Noh Y, Kim JS. [18F]THK-5351 PET Patterns in Patients With
Alzheimer's Disease and Negative Amyloid PET Findings. J Clin Neurol. 2022
Jul;18(4):437-446. doi: 10.3988/jcn.2022.18.4.437. PMID: 35796269; PMCID:
PMC9262461.

2: Huang CC, Hsiao IT, Huang CY, Weng YC, Huang KL, Liu CH, Chang TY, Wu HC, Yen
TC, Lin KJ. Tau PET With 18F-THK-5351 Taiwan Patients With Familial
Alzheimer's Disease With the APP p.D678H Mutation. Front Neurol. 2019 May
22;10:503. doi: 10.3389/fneur.2019.00503. PMID: 31191427; PMCID: PMC6538951.

3: Park S, Oh M, Kim JS, Lee JH, Yoon YW, Roh JH. 18F-THK-5351,
Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer's Disease:
A Pictorial Insight into Disease Pathophysiology. Brain Sci. 2021 Apr
6;11(4):465. doi: 10.3390/brainsci11040465. PMID: 33917613; PMCID: PMC8067517.

4: Kobayashi R, Hayashi H, Kawakatsu S, Ishiki A, Okamura N, Arai H, Otani K.
[18F]THK-5351 PET imaging in early-stage semantic variant primary
progressive aphasia: a report of two cases and a literature review. BMC Neurol.
2018 Aug 8;18(1):109. doi: 10.1186/s12883-018-1115-3. PMID: 30089453; PMCID:
PMC6205153.

5: Stepanov V, Svedberg M, Jia Z, Krasikova R, Lemoine L, Okamura N, Furumoto S,
Mitsios N, Mulder J, Långström B, Nordberg A, Halldin C. Development of
[11C]/[3H]THK-5351 - A potential novel carbon-11 tau
imaging PET radioligand. Nucl Med Biol. 2017 Mar;46:50-53. doi:
10.1016/j.nucmedbio.2016.12.004. Epub 2016 Dec 9. PMID: 28013122.

6: Huang KL, Hsu JL, Lin KJ, Chang CH, Wu YM, Chang TY, Chang YJ, Liu CH, Ho MY,
Wey SP, Yen TC, Okamura N, Hsiao IT, Lee TH. Visualization of ischemic stroke-
related changes on 18F-THK-5351 positron emission tomography. EJNMMI
Res. 2018 Jul 16;8(1):62. doi: 10.1186/s13550-018-0417-1. PMID: 30014313; PMCID:
PMC6047954.

7: Park JE, Yun J, Kim SJ, Shim WH, Oh JS, Oh M, Roh JH, Seo SW, Oh SJ, Kim JS.
Intra-individual correlations between quantitative THK-5351 PET and MRI-derived
cortical volume in Alzheimer's disease differ according to disease severity and
amyloid positivity. PLoS One. 2019 Dec 13;14(12):e0226265. doi:
10.1371/journal.pone.0226265. PMID: 31834916; PMCID: PMC6910674.

8: Kim M, Kim SJ, Park JE, Yun J, Shim WH, Oh JS, Oh M, Roh JH, Seo SW, Oh SJ,
Kim JS. Combination of automated brain volumetry on MRI and quantitative tau
deposition on THK-5351 PET to support diagnosis of Alzheimer's disease. Sci Rep.
2021 May 14;11(1):10343. doi: 10.1038/s41598-021-89797-x. PMID: 33990649; PMCID:
PMC8121780.

9: Harada R. [Imaging of neuropathology by PET tracers]. Nihon Yakurigaku
Zasshi. 2022;157(6):453-457. Japanese. doi: 10.1254/fpj.22061. PMID: 36328560.